Summary
Over a 24-week period, a combination of empagliflozin/linagliptin for the treatment of type 2 diabetes produced significant reductions in HbA1c compared with linagliptin and with empagliflozin 10 mg, but not empagliflozin 25 mg. This randomized trial suggests that this approach could be a more efficient way to achieve glycemic control.
- linagliptin
- empagliflozin
- diabetes mellitus
- DPP-4 inhibitor
- SGLT2 inhibitor
- HbA1c
- incretin peptides
- GLP-1
- glucagon
- endocrinology, diabetes & metabolism clinical trials
- hyperglycemia/hypoglycemia
- © 2015 SAGE Publications
Tools
Significant HbA1c Reduction With Empagliflozin/Linagliptin Combination
Permalink:
Table of contents
Cited By...
- No citing articles found.